15-Deoxy-Δ12,14-prostaglandin J2 down-regulates CXCR4 on carcinoma cells through PPARγ- and NFκB-mediated pathways

Experimental Cell Research

Volumn 313, Issue 16, 2007, Pages 3446-3458

  Richard, Cynthia Lee ^a   Lowthers, Erica Lauren ^a   Blay, Jonathan ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Colorectal carcinoma; CXCL12; CXCR4; Eicosanoids; Invasion; Metastasis; NF B; PPAR ; Thiazolidinediones; Tumor microenvironment

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2 CHLORO 5 NITRO N (4 PYRIDYL)BENZAMIDE; 2 CHLORO 5 NITROBENZANILIDE; CAY 10410; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN A2; PROSTAGLANDIN D2; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E2; PROSTAGLANDIN J2; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ARTICLE; CARCINOMA CELL; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; HUMAN; HUMAN CELL; IMMUNOLOCALIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEPTOR DOWN REGULATION;

EID: 34548640206     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2007.06.027     Document Type: Article

References (87)

1. Raghunand N., Gatenby R.A., and Gillies R.J. Microenvironmental and cellular consequences of altered blood flow in tumours. Br. J. Radiol. 6 (2003) S11-S22
2. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin. Radiat. Oncol. 14 (2004) 198-206
3. Sulitzeanu D. Immunosuppressive factors in human cancer. Adv. Cancer Res. 60 (1993) 247-267
4. Kopfstein L., and Christofori G. Metastasis: cell-autonomous mechanisms versus contributions by the tumor microenvironment. Cell. Mol. Life Sci. 63 (2006) 449-468
5. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294 (2001) 1871-1875
6. Gupta R.A., and Dubois R.N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer 1 (2001) 11-21
7. Marnett L.J., and DuBois R.N. COX-2: a target for colon cancer prevention. Annu. Rev. Pharmacol. Toxicol. 42 (2002) 55-80
8. Brown J.R., and DuBois R.N. COX-2: a molecular target for colorectal cancer prevention. J. Clin. Oncol. 23 (2005) 2840-2855
9. Wang D., Mann J.R., and DuBois R.N. The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology 128 (2005) 1445-1461
10. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., and DuBois R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107 (1994) 1183-1188
11. Kutchera W., Jones D.A., Matsunami N., Groden J., McIntyre T.M., Zimmerman G.A., White R.L., and Prescott S.M. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 4816-4820
12. Dimberg J., Samuelsson A., Hugander A., and Söderkvist P. Differential expression of cyclooxygenase 2 in human colorectal cancer. Gut 45 (1999) 730-732
13. Djazayeri K., Szilvássy Z., Peitl B., Németh J., Nagy L., Kiss A., Szabó B., and Benkõ I. Accelerated recovery of 5-fluorouracil-damaged bone marrow after rosiglitazone treatment. Eur. J. Pharmacol. 522 (2005) 122-129
14. Soumaoro L.T., Uetake H., Higuchi T., Takagi Y., Enomoto M., and Sugihara K. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin. Cancer Res. 10 (2004) 8465-8471
15. 2 in human colorectal cancer. Anticancer Res. 18 (1998) 3283-3287
16. 2. Gut 35 (1994) 675-678
17. Giardiello F.M., Spannhake E.W., DuBois R.N., Hylind L.M., Robinson C.R., Hubbard W.C., Hamilton S.R., and Yang V.W. Prostaglandin levels in human colorectal mucosa: effects of sulindac in patients with familial adenomatous polyposis. Dig. Dis. Sci. 43 (1998) 311-316
18. Rigas B., Goldman I.S., and Levine L. Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med. 122 (1993) 518-523
19. Qiao L., Kozoni V., Tsioulias G.J., Koutsos M.I., Hanif R., Shiff S.J., and Rigas B. Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. Biochim. Biophys. Acta 1258 (1995) 215-223
20. 2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat. Med. 8 (2002) 289-293
21. Wang D., Buchanan F.G., Wang H., Dey S.K., and DuBois R.N. Prostaglandin E2 enhances intestinal adenoma growth via activation of the ras-mitogen-activated protein kinase cascade. Cancer Res. 65 (2005) 1822-1829
22. Blay J., and Brown K.D. Epidermal growth factor promotes the chemotactic migration of cultured rat intestinal epithelial cells. J. Cell. Physiol. 124 (1985) 107-112
23. Blay J., and Brown K.D. Functional receptors for epidermal growth factor in an epithelial-cell line derived from the rat small intestine. Biochem. J. 225 (1985) 85-94
24. 2 receptors in migration of murine and human breast cancer cells. Exp. Cell Res. 289 (2003) 265-274
25. Chang S.H., Liu C.H., Conway R., Han D.K., Nithipatikom K., Trifan O.C., Lane T.F., and Hla T. Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 591-596
26. Langberg H., Boushel R., Skovgaard D., Risum N., and Kjaer M. Cyclo-oxygenase-2 mediated prostaglandin release regulates blood flow in connective tissue during mechanical loading in humans. J. Physiol. 551 (2003) 683-689
27. 2 in acute renal hypoperfusion. Nephrology 8 (2003) 65-71
28. 14C]-arachidonic acid by human colonic mucosa. Gut 24 (1983) 1176-1182
29. Aussel C., Mary D., and Fehlmann M. Prostaglandin synthesis in human T cells: its partial inhibition by lectins and anti-CD3 antibodies as a possible step in T cell activation. J. Immunol. 138 (1987) 3094-3099
30. 2α by decidual stromal cells and macrophages in culture. Eicosanoids 4 (1991) 203-207
31. 2. Identification of products formed in vitro. J. Biol. Chem. 258 (1983) 11713-11718
32. 2 against the proliferation of human colon cancer cell lines and hepatic metastasis from colorectal cancer. Surg. Today 28 (1998) 740-745
33. Kitamura S., Miyazaki Y., Shinomura Y., Kondo S., Kanayama S., and Matsuzawa Y. Peroxisome proliferator-activated receptor γ induces growth arrest and differentiation markers of human colon cancer cells. Jpn. J. Cancer Res. 90 (1999) 75-80
34. Shimada T., Kojima K., Yoshiura K., Hiraishi H., and Terano A. Characteristics of the peroxisome proliferator activated receptor γ (PPARγ) ligand induced apoptosis in colon cancer cells. Gut 50 (2002) 658-664
35. 2 in colon carcinoma cells: evidence for a redox-sensitive peroxisome proliferator-activated receptor-γ-independent mechanism. Cancer Res. 64 (2004) 5162-5171
36. Tachibana K., Hirota S., Iizasa H., Yoshida H., Kawabata K., Kataoka Y., Kitamura Y., Matsushima K., Yoshida N., Nishikawa S., Kishimoto T., and Nagasawa T. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 393 (1998) 591-594
37. Dwinell M.B., Eckmann L., Leopard J.D., Varki N.M., and Kagnoff M.F. Chemokine receptor expression by human intestinal epithelial cells. Gastroenterology 117 (1999) 359-367
38. Jordan N.J., Kolios G., Abbot S.E., Sinai M.A., Thompson D.A., Petraki K., and Westwick J. Expression of functional CXCR4 chemokine receptors on human colonic epithelial cells. J. Clin. Invest. 104 (1999) 1061-1069
39. Zeelenberg I.S., Ruuls-Van Stalle L., and Roos E. The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res. 63 (2003) 3833-3839
40. Ottaiano A., di Palma A., Napolitano M., Pisano C., Pignata S., Tatangelo F., Botti G., Acquaviva A.M., Castello G., Ascierto P.A., Iaffaioli R.V., and Scala S. Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells. Cancer Immunol. Immunother. 54 (2005) 781-791
41. Schimanski C.C., Schwald S., Simiantonaki N., Jayasinghe C., Gönner U., Wilsberg V., Junginger T., Berger M.R., Galle P.R., and Moehler M. Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin. Cancer Res. 11 (2005) 1743-1750
42. Kim J., Takeuchi H., Lam S.T., Turner R.R., Wang H.J., Kuo C., Foshag L., Bilchik A.J., and Hoon D.S. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J. Clin. Oncol. 23 (2005) 2744-2753
43. Ottaiano A., Franco R., Aiello Talamanca A., Liguori G., Tatangelo F., Delrio P., Nasti G., Barletta E., Facchini G., Daniele B., Di Blasi A., Napolitano M., Ierano C., Calemma R., Leonardi E., Albino V., De Angelis V., Falanga M., Boccia V., Capuozzo M., Parisi V., Botti G., Castello G., Vincenzo Iaffaioli R., and Scala S. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clin. Cancer Res. 12 (2006) 2795-2803
44. Richard C.L., Tan E.Y., and Blay J. Adenosine up-regulates CXCR4 and enhances the proliferative and migratory responses of human carcinoma cells to CXCL12/SDF-1α. Int. J. Cancer 119 (2006) 2044-2053
45. - ΔΔ cT method. Methods 25 (2001) 402-408
46. Tan E.Y., Mujoomdar M., and Blay J. Adenosine down-regulates the surface expression of dipeptidyl peptidase IV on HT-29 human colorectal carcinoma cells: Implications for cancer cell behaviour. Am. J. Pathol. 165 (2004) 319-330
47. Tan E.Y., Richard C.L., Zhang H., Hoskin D.W., and Blay J. Adenosine down-regulates DPPIV on HT-29 colon cancer cells by stimulating protein tyrosine phosphatase(s) and reducing ERK1/2 activity via a novel pathway. Am. J. Physiol. Cell Physiol. 291 (2006) C433-C444
48. 2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells. Blood 102 (2003) 1966-1977
49. Goichberg P., Kalinkovich A., Borodovsky N., Tesio M., Petit I., Nagler A., Hardan I., and Lapidot T. cAMP-induced PKCζ activation increases functional CXCR4 expression on human CD34+ hematopoietic progenitors. Blood 107 (2006) 870-879
50. 2 in the differentiation of dendritic cells: how do dendritic cells influence T-cell polarization and chemokine receptor expression?. Stem Cells 20 (2002) 448-459
51. 2 is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptors. J. Immunol. 176 (2006) 966-973
52. 2 is a ligand for the adipocyte determination factor PPAR γ. Cell 83 (1995) 803-812
53. Shiraki T., Kamiya N., Shiki S., Kodama T.S., Kakizuka A., and Jingami H. α,β-Unsaturated ketone is a core moiety of natural ligands for covalent binding to peroxisome proliferator-activated receptor γ. J. Biol. Chem. 280 (2005) 14145-14153
54. Rossi A., Kapahi P., Natoli G., Takahashi T., Chen Y., Karin M., and Santoro M.G. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature 403 (2000) 103-108
55. 2 inhibits multiple steps in the NF-κ B signaling pathway. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 4844-4849
56. 2 inhibits interleukin-1β-induced nuclear factor-κb in human amnion and myometrial cells: Mechanisms and implications. J. Clin. Endocrinol. Metab. 90 (2005) 3534-3543
57. 2 production. Br. J. Pharmacol. 144 (2005) 338-348
58. Hata A.N., and Breyer R.M. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol. Ther. 103 (2004) 147-166
59. Cristillo A.D., Highbarger H.C., Dewar R.L., Dimitrov D.S., Golding H., and Bierer B.E. Up-regulation of HIV coreceptor CXCR4 expression in human T lymphocytes is mediated in part by a cAMP-responsive element. FASEB J. 16 (2002) 354-364
60. 2+ mobilization and cAMP in HT-29 human colon adenocarcinoma cells. Cancer Lett. 152 (2000) 217-222
61. 2, in HT-29 human colon cancer cell line. Auton. Autacoid Pharmacol. 23 (2003) 193-199
62. 2 receptors DP1 and DP2 by human colorectal cancer cells. Cancer Lett. 210 (2004) 81-84
63. 2 exerting cell growth inhibition. Biochem. Biophys. Res. Commun. 127 (1985) 739-745
64. 2 metabolite generated during inflammatory processes. J. Biol. Chem. 277 (2002) 10459-10466
65. Kim J., Yang P., Suraokar M., Sabichi A.L., Llansa N.D., Mendoza G., Subbarayan V., Logothetis C.J., Newman R.A., Lippman S.M., and Menter D.G. Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. Cancer Res. 65 (2005) 6189-6198
66. 2 metabolism in plasma: kinetics and relationship with bioactivity on DP1 and CRTH2 receptors. Biochem. Pharmacol. 74 (2007) 107-117
67. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 83 (1995) 813-819
68. Kliewer S.A., Sundseth S.S., Jones S.A., Brown P.J., Wisely G.B., Koble C.S., Devchand P., Wahli W., Willson T.M., Lenhard J.M., and Lehmann J.M. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 4318-4323
69. Kota B.P., Huang T.H., and Roufogalis B.D. An overview on biological mechanisms of PPARs. Pharmacol. Res. 51 (2005) 85-94
70. Grommes C., Landreth G.E., and Heneka M.T. Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists. Lancet Oncol. 5 (2004) 419-429
71. Ricote M., Li A.C., Willson T.M., Kelly C.J., and Glass C.K. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391 (1998) 79-82
72. Pascual G., Fong A.L., Ogawa S., Gamliel A., Li A.C., Perissi V., Rose D.W., Willson T.M., Rosenfeld M.G., and Glass C.K. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ. Nature 437 (2005) 759-763
73. Koeffler H.P. Peroxisome proliferator-activated receptor γ and cancers. Clin. Cancer Res. 9 (2003) 1-9
74. Sarraf P., Mueller E., Jones D., King F.J., DeAngelo D.J., Partridge J.B., Holden S.A., Chen L.B., Singer S., Fletcher C., and Spiegelman B.M. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat. Med. 4 (1998) 1046-1052
75. Feilchenfeldt J., Brundler M.A., Soravia C., Tötsch M., and Meier C.A. Peroxisome proliferator-activated receptors (PPARs) and associated transcription factors in colon cancer: Reduced expression of PPARγ-coactivator 1 (PGC-1). Cancer Lett. 203 (2004) 25-33
76. Matthiessen M.W., Pedersen G., Albrektsen T., Adamsen S., Fleckner J., and Brynskov J. Peroxisome proliferator-activated receptor expression and activation in normal human colonic epithelial cells and tubular adenomas. Scand. J. Gastroenterol. 40 (2005) 198-205
77. Yang W.L., and Frucht H. Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis 22 (2001) 1379-1383
78. Yoshizumi T., Ohta T., Ninomiya I., Terada I., Fushida S., Fujimura T., Nishimura G., Shimizu K., Yi S., and Miwa K. Thiazolidinedione, a peroxisome proliferator-activated receptor-γ ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects. Int. J. Oncol. 25 (2004) 631-639
79. Helbig G., Christopherson II K.W., Bhat-Nakshatri P., Kumar S., Kishimoto H., Miller K.D., Broxmeyer H.E., and Nakshatri H.E. NF-κB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J. Biol. Chem. 278 (2003) 21631-21638
80. 2 inhibition of NF-κB-DNA binding through covalent modification of the p50 subunit. J. Biol. Chem. 276 (2001) 35530-35536
81. Ponferrada A., Caso J.R., Alou L., Colón A., Sevillano D., Moro M.A., Lizasoain I., Menchén P., Gómez-Lus M.L., Lorenzo P., Cos E., Leza J.C., and Menchén L. The role of PPARgamma on restoration of colonic homeostasis after experimental stress-induced inflammation and dysfunction. Gastroenterology 132 (2007) 1791-1803
82. Schioppa T., Uranchimeg B., Saccani A., Biswas S.K., Doni A., Rapisarda A., Bernasconi A., Saccani S., Nebuloni M., Vago L., Mantovani A., Melillo G., and Sica A. Regulation of the chemokine receptor CXCR4 by hypoxia. J. Exp. Med. 198 (2003) 1391-1402
83. Staller P., Sulitkova J., Lisztwan J., Moch H., Oakeley E.J., and Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425 (2003) 307-311
84. Bachelder R.E., Wendt M.A., and Mercurio A.M. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res. 62 (2002) 7203-7206
85. Kulbe H., Hagemann T., Szlosarek P.W., Balkwill F.R., and Wilson J.L. The inflammatory cytokine tumor necrosis factor-α regulates chemokine receptor expression on ovarian cancer cells. Cancer Res. 65 (2005) 10355-10362
86. Bartolomé R.A., Gálvez B.G., Longo N., Baleux F., Van Muijen G.N., Sánchez-Mateos P., Arroyo A.G., and Teixidó J. Stromal cell-derived factor-1α promotes melanoma cell invasion across basement membranes involving stimulation of membrane-type 1 matrix metalloproteinase and Rho GTPase activities. Cancer Res. 64 (2004) 2534-2543
87. Richard C.L., and Blay J. Thiazolidinedione drugs down-regulate CXCR4 expression on human colorectal cancer cells in a peroxisome proliferator activated receptor-γ-dependent manner. Int. J. Oncol. 30 (2007) 1215-1222